Black Friday Deals with Eden. Unlock the New You, Today!
Get started
Weight Loss

Semaglutide vs. Tirzepatide: Prices, Reviews, Pros & Cons

Explore the differences between Semaglutide and Tirzepatide for weight management. Discover their benefits, side effects, and effectiveness in our in-depth comparison.

Clinically proven

weight loss treatment

whole body health treatment

Compounded Semaglutide

As low as  
$176
/mo
As low as  
$276
/mo
In stock
Limited supply
Semaglutide

Oral Semaglutide

As low as  
/mo
As low as  
/mo
$246/mo
$196/1st mo
$246/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & MIC+B12

As low as  
$276
/mo
As low as  
$296
/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & Sermorelin

As low as  
/mo
As low as  
$406
/mo
In stock
Limited supply
Semaglutide

Compounded Semaglutide & Sermorelin & MIC+B12

As low as  
/mo
As low as  
$476
/mo
In stock
Limited supply
Semaglutide

Overview

Explore the impact of semaglutide and tirzepatide, two cutting-edge medications against obesity. Delve into their mechanisms, benefits, and differences, providing a comprehensive analysis of their roles in weight management.

The struggle with obesity and weight management has long plagued millions worldwide. While diet and exercise remain crucial, the role of medication in addressing this complex issue cannot be understated. Among the recent breakthroughs, two innovative drugs, semaglutide (Wegovy) and tirzepatide (Mounjaro), have garnered significant attention for their remarkable weight loss results. In this article, we'll delve into the similarities, differences, and potential implications of these groundbreaking medications.

Semaglutide: The Established Contender

Semaglutide, often hailed as a game-changer in diabetes management, has garnered significant attention for its efficacy in glycemic control and potential for weight loss. It works by mimicking the action of GLP-1, a hormone that regulates blood sugar levels, while also slowing gastric emptying, leading to a feeling of fullness.

One of the key features of semaglutide is its convenient once-weekly dosing regimen, administered via a simple subcutaneous injection. This dosing frequency offers flexibility and convenience for individuals managing their diabetes amidst busy schedules.

Studies have shown that semaglutide can effectively lower blood sugar levels, reduce the risk of cardiovascular events, and promote weight loss in people with type 2 diabetes. Its comprehensive benefits make it a popular choice among healthcare providers and patients alike.

Tirzepatide: The New Kid on the Block

Enter tirzepatide, the newcomer to the GLP-1 RA scene, boasting impressive results in clinical trials and stirring excitement within the diabetes community. Like semaglutide, tirzepatide works by activating GLP-1 receptors, but it also simultaneously targets another hormone receptor called glucose-dependent insulinotropic polypeptide (GIP).

This dual action sets tirzepatide apart, offering the potential for even greater reductions in blood sugar levels and weight loss compared to semaglutide. Additionally, tirzepatide has demonstrated a lower risk of hypoglycemia, making it an attractive option for individuals who are prone to low blood sugar episodes.

Similar to semaglutide, tirzepatide is administered via a once-weekly subcutaneous injection, providing convenience and ease of use for patients seeking effective diabetes management.

Important Update: With the recent announcement from Zepbound that the shortage of tirzepatide is now over, compounded tirzepatide has been banned nationwide in the US. You can keep up to date on announcements in our guide about the tirzepatide shortage.

Comparing Semaglutide and Tirzepatide

When considering semaglutide and tirzepatide, several factors come into play, influencing the decision-making process for both patients and healthcare providers.

  1. Efficacy: Both semaglutide and tirzepatide have shown efficacy in lowering blood sugar levels and promoting weight loss. However, tirzepatide's dual mechanism of action may confer additional benefits in terms of glycemic control and weight management.
  2. Safety: Both medications are generally well-tolerated, with common side effects including gastrointestinal symptoms such as nausea and vomiting. However, tirzepatide has shown a lower risk of hypoglycemia compared to semaglutide, which may be advantageous for certain individuals, particularly those at higher risk of low blood sugar episodes.
  3. Convenience: With once-weekly dosing, both semaglutide and tirzepatide offer convenience and flexibility for patients. The simplicity of administration may contribute to better adherence to treatment regimens.

Making the Right Choice for You

Ultimately, the decision between semaglutide and tirzepatide should be made in consultation with a healthcare provider, taking into account individual factors such as medical history, treatment goals, and preferences.

Both medications offer valuable options for weight loss and diabetes management, each with its own unique benefits and considerations. By discussing your options openly and collaboratively with your healthcare team, you can navigate the choices available and determine the best course of action for your journey. They may even suggest you switch from semaglutide to tirzepatide (or vice versa) if one medication doesn't agree with you.

Clinical Trial Results

Semaglutide

In the pivotal STEP clinical trial program, participants receiving semaglutide 2.4 mg once weekly lost an average of 14.9% of their initial body weight after 68 weeks of treatment, compared to 2.4% for those on placebo.1

Tirzepatide

The SURPASS clinical trial program demonstrated impressive weight loss results with tirzepatide. At the highest dose of 15 mg once weekly, participants lost an average of 22.5% of their initial body weight after 72 weeks, significantly outperforming semaglutide and placebo groups.2

Potential Side Effects

Both semaglutide and tirzepatide share similar side effect profiles, as they belong to the same class of medications. The most common side effects include:

These side effects are generally mild to moderate and tend to diminish over time as the body adjusts to the medication. However, more severe side effects, such as pancreatitis and thyroid tumor development, have been reported in rare cases.3,4

It's essential to discuss potential risks and benefits with a healthcare provider before starting either medication.

Semaglutide and Tirzepatide Dosing and Administration

Semaglutide:

Starting dose: 0.25 mg once weekly

Dose escalation: Increased by 0.25 mg every 4 weeks until reaching the maintenance dose of 2.4 mg once weekly

Tirzepatide:

Starting dose: 2.5 mg once weekly

Dose escalation: Increased by 2.5 mg every 4 weeks until reaching the maximum dose

Both medications are administered via subcutaneous (under the skin) injection, typically in the abdomen, thigh, or upper arm area.

Comprehensive Weight Management Approach

While semaglutide and tirzepatide have demonstrated remarkable weight loss results, it's important to note that they should be used as part of a comprehensive weight management program. This includes adopting a healthy, calorie-controlled diet and engaging in regular physical activity. These medications are not a substitute for lifestyle modifications but rather a complementary tool to support weight loss efforts.

Cost and Accessibility

The cost of these medications can be a significant consideration for many patients.

At Eden, our semaglutide and tirzepatide treatments remain the same price at every dose. No insurance needed.

Compounded Tirzepatide: $396 per month

Compounded Semaglutide (Injection): $296 per month

Frequently Asked Questions

Are semaglutide and tirzepatide suitable for long-term use?

Yes, both medications are intended for long-term use as part of a comprehensive weight management program. However, regular monitoring by a healthcare provider is recommended to assess effectiveness and potential side effects.

Can these medications be used by individuals without obesity or being overweight?

No, semaglutide and tirzepatide are currently approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia.

Can semaglutide and tirzepatide be used together or with other weight loss medications?

No, it is not recommended to use these medications in combination with other GLP-1 receptor agonists, as the safety and efficacy of such combinations has not been established.

Are there any contraindications or precautions for these medications?

Both semaglutide and tirzepatide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additionally, they should be used with caution in individuals with kidney or liver disease.

Semaglutide and tirzepatide represent significant advancements in the field of weight loss medication, offering promising solutions for individuals struggling with obesity and related health conditions. While both medications share similarities in their mechanisms of action and side effect profiles, tirzepatide's dual-receptor targeting approach has demonstrated superior weight loss results in clinical trials.

However, it's crucial to remember that these medications should be used as part of a comprehensive weight management program that includes lifestyle modifications. As with any medication, a thorough discussion with a healthcare provider is essential to weigh the potential risks and benefits and determine the most appropriate treatment option.

As research continues to evolve, the availability of effective and safe weight loss medications like semaglutide and tirzepatide offers hope for those seeking sustainable solutions in their journey toward better health and well-being.

Disclaimer

The information provided in this article is for educational purposes only and not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition or treatment options. For a full list of important safety information, disclaimers, and terms and conditions of use, please visit tryeden.com/safety-info.

Clinically proven weight loss treatments

GLP-1 medications

Starting at $179/mo
No items found.

Start your health journey now

On-demand medical support, 100% online
Transparent pricing for every single dose
Tested lots for potency, sterility, pH and endotoxicity
Transparent pricing for every single dose
Weight Loss
Semaglutide vs. Tirzepatide: Prices, Reviews, Pros & Cons
Full name
December 6, 2024
5
 min read

The struggle with obesity and weight management has long plagued millions worldwide. While diet and exercise remain crucial, the role of medication in addressing this complex issue cannot be understated. Among the recent breakthroughs, two innovative drugs, semaglutide (Wegovy) and tirzepatide (Mounjaro), have garnered significant attention for their remarkable weight loss results. In this article, we'll delve into the similarities, differences, and potential implications of these groundbreaking medications.

Semaglutide: The Established Contender

Semaglutide, often hailed as a game-changer in diabetes management, has garnered significant attention for its efficacy in glycemic control and potential for weight loss. It works by mimicking the action of GLP-1, a hormone that regulates blood sugar levels, while also slowing gastric emptying, leading to a feeling of fullness.

One of the key features of semaglutide is its convenient once-weekly dosing regimen, administered via a simple subcutaneous injection. This dosing frequency offers flexibility and convenience for individuals managing their diabetes amidst busy schedules.

Studies have shown that semaglutide can effectively lower blood sugar levels, reduce the risk of cardiovascular events, and promote weight loss in people with type 2 diabetes. Its comprehensive benefits make it a popular choice among healthcare providers and patients alike.

Tirzepatide: The New Kid on the Block

Enter tirzepatide, the newcomer to the GLP-1 RA scene, boasting impressive results in clinical trials and stirring excitement within the diabetes community. Like semaglutide, tirzepatide works by activating GLP-1 receptors, but it also simultaneously targets another hormone receptor called glucose-dependent insulinotropic polypeptide (GIP).

This dual action sets tirzepatide apart, offering the potential for even greater reductions in blood sugar levels and weight loss compared to semaglutide. Additionally, tirzepatide has demonstrated a lower risk of hypoglycemia, making it an attractive option for individuals who are prone to low blood sugar episodes.

Similar to semaglutide, tirzepatide is administered via a once-weekly subcutaneous injection, providing convenience and ease of use for patients seeking effective diabetes management.

Important Update: With the recent announcement from Zepbound that the shortage of tirzepatide is now over, compounded tirzepatide has been banned nationwide in the US. You can keep up to date on announcements in our guide about the tirzepatide shortage.

Comparing Semaglutide and Tirzepatide

When considering semaglutide and tirzepatide, several factors come into play, influencing the decision-making process for both patients and healthcare providers.

  1. Efficacy: Both semaglutide and tirzepatide have shown efficacy in lowering blood sugar levels and promoting weight loss. However, tirzepatide's dual mechanism of action may confer additional benefits in terms of glycemic control and weight management.
  2. Safety: Both medications are generally well-tolerated, with common side effects including gastrointestinal symptoms such as nausea and vomiting. However, tirzepatide has shown a lower risk of hypoglycemia compared to semaglutide, which may be advantageous for certain individuals, particularly those at higher risk of low blood sugar episodes.
  3. Convenience: With once-weekly dosing, both semaglutide and tirzepatide offer convenience and flexibility for patients. The simplicity of administration may contribute to better adherence to treatment regimens.

Making the Right Choice for You

Ultimately, the decision between semaglutide and tirzepatide should be made in consultation with a healthcare provider, taking into account individual factors such as medical history, treatment goals, and preferences.

Both medications offer valuable options for weight loss and diabetes management, each with its own unique benefits and considerations. By discussing your options openly and collaboratively with your healthcare team, you can navigate the choices available and determine the best course of action for your journey. They may even suggest you switch from semaglutide to tirzepatide (or vice versa) if one medication doesn't agree with you.

Clinical Trial Results

Semaglutide

In the pivotal STEP clinical trial program, participants receiving semaglutide 2.4 mg once weekly lost an average of 14.9% of their initial body weight after 68 weeks of treatment, compared to 2.4% for those on placebo.1

Tirzepatide

The SURPASS clinical trial program demonstrated impressive weight loss results with tirzepatide. At the highest dose of 15 mg once weekly, participants lost an average of 22.5% of their initial body weight after 72 weeks, significantly outperforming semaglutide and placebo groups.2

Potential Side Effects

Both semaglutide and tirzepatide share similar side effect profiles, as they belong to the same class of medications. The most common side effects include:

These side effects are generally mild to moderate and tend to diminish over time as the body adjusts to the medication. However, more severe side effects, such as pancreatitis and thyroid tumor development, have been reported in rare cases.3,4

It's essential to discuss potential risks and benefits with a healthcare provider before starting either medication.

Semaglutide and Tirzepatide Dosing and Administration

Semaglutide:

Starting dose: 0.25 mg once weekly

Dose escalation: Increased by 0.25 mg every 4 weeks until reaching the maintenance dose of 2.4 mg once weekly

Tirzepatide:

Starting dose: 2.5 mg once weekly

Dose escalation: Increased by 2.5 mg every 4 weeks until reaching the maximum dose

Both medications are administered via subcutaneous (under the skin) injection, typically in the abdomen, thigh, or upper arm area.

Comprehensive Weight Management Approach

While semaglutide and tirzepatide have demonstrated remarkable weight loss results, it's important to note that they should be used as part of a comprehensive weight management program. This includes adopting a healthy, calorie-controlled diet and engaging in regular physical activity. These medications are not a substitute for lifestyle modifications but rather a complementary tool to support weight loss efforts.

Cost and Accessibility

The cost of these medications can be a significant consideration for many patients.

At Eden, our semaglutide and tirzepatide treatments remain the same price at every dose. No insurance needed.

Compounded Tirzepatide: $396 per month

Compounded Semaglutide (Injection): $296 per month

Frequently Asked Questions

Are semaglutide and tirzepatide suitable for long-term use?

Yes, both medications are intended for long-term use as part of a comprehensive weight management program. However, regular monitoring by a healthcare provider is recommended to assess effectiveness and potential side effects.

Can these medications be used by individuals without obesity or being overweight?

No, semaglutide and tirzepatide are currently approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidemia.

Can semaglutide and tirzepatide be used together or with other weight loss medications?

No, it is not recommended to use these medications in combination with other GLP-1 receptor agonists, as the safety and efficacy of such combinations has not been established.

Are there any contraindications or precautions for these medications?

Both semaglutide and tirzepatide should not be used by individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Additionally, they should be used with caution in individuals with kidney or liver disease.

Semaglutide and tirzepatide represent significant advancements in the field of weight loss medication, offering promising solutions for individuals struggling with obesity and related health conditions. While both medications share similarities in their mechanisms of action and side effect profiles, tirzepatide's dual-receptor targeting approach has demonstrated superior weight loss results in clinical trials.

However, it's crucial to remember that these medications should be used as part of a comprehensive weight management program that includes lifestyle modifications. As with any medication, a thorough discussion with a healthcare provider is essential to weigh the potential risks and benefits and determine the most appropriate treatment option.

As research continues to evolve, the availability of effective and safe weight loss medications like semaglutide and tirzepatide offers hope for those seeking sustainable solutions in their journey toward better health and well-being.

Disclaimer

The information provided in this article is for educational purposes only and not intended to replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health providers with any questions you may have regarding a medical condition or treatment options. For a full list of important safety information, disclaimers, and terms and conditions of use, please visit tryeden.com/safety-info.

Share this post

Subscribe to our newsletter

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Everyday Eden

Featured Treatments

*Only available if prescribed after an online consultation with a healthcare provider. *Benefits outlined on TryEden are based on third-party studies. Plans are offered as a subscription service which you can cancel at any time. *Actual product packaging may appear differently than shown. Physicians may prescribe compounded medications as needed to meet patient requirements or drug shortages. *The FDA does not review or approve any compounded medications for safety or effectiveness. *Has not been approved by the FDA for these uses but studies have shown benefits. Results may vary.

The Science

Supporting research citations are below

1. Ozempic®, a GLP-1 receptor agonist, is approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Clinical trials showed it effectively lowers HbA1c and body weight, regardless of sex, race, or age. While offering significant benefits, it may cause side effects like gastrointestinal issues, with serious risks including pancreatitis and potential cancer based on animal studies. The drug's efficacy and side effect profile were consistent across diverse demographic groups. Trials involved over 4,000 participants worldwide, further highlighting its global applicability and safety profile for a broad patient population.

1. Ozempic®, a GLP-1 receptor agonist, is approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Clinical trials showed it effectively lowers HbA1c and body weight, regardless of sex, race, or age. While offering significant benefits, it may cause side effects like gastrointestinal issues, with serious risks including pancreatitis and potential cancer based on animal studies. The drug's efficacy and side effect profile were consistent across diverse demographic groups. Trials involved over 4,000 participants worldwide, further highlighting its global applicability and safety profile for a broad patient population.

1. Ozempic®, a GLP-1 receptor agonist, is approved for improving blood sugar control in adults with type 2 diabetes when used alongside diet and exercise. Clinical trials showed it effectively lowers HbA1c and body weight, regardless of sex, race, or age. While offering significant benefits, it may cause side effects like gastrointestinal issues, with serious risks including pancreatitis and potential cancer based on animal studies. The drug's efficacy and side effect profile were consistent across diverse demographic groups. Trials involved over 4,000 participants worldwide, further highlighting its global applicability and safety profile for a broad patient population.

Should you seek a prescription item, Eden will facilitate arranging a consultation with a qualified healthcare provider. This professional will assess your suitability for the prescription item. If deemed suitable, a doctor may issue a prescription for the item, which can be filled at a partner pharmacy, unless you specify an alternative preference.

Note: The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.